Founder
Jibin Yu (Chairman and CEO)
His career highlights include pioneering one of China's earliest industrialized gene synthesis processes at Shanghai Bioasia Biotechnology (acquired by Invitrogen/Thermo Fisher in 2004). In 2005, he joined Nanjing GenScript Biotech (H.K.01548), rising swiftly to vice president and playing a key role in its transformation into the world's largest gene synthesis center, culminating in its 2015 Hong Kong Stock Exchange listing. His innovative leadership has also propelled subsidiaries like Legend Biotech (NASDAQ: LEGN) to global prominence.
In 2016, Mr. Yu founded Suzhou Xianda Gene Technology Co., Ltd., leveraging deep mastery in PCR and nucleic acid technologies to develop proprietary ERA and NEW ERA isothermal amplification systems. Integrated with the compact Gene Mirror handheld device and mobile app, these innovations enable rapid (10-15 minute) on-site nucleic acid detection with real-time data upload and epidemic mapping.
Today, Xianda's solutions span food safety, animal health, molecular diagnostics, and POCT. A member of the National Health Industry Enterprise Management Association, the company completed Pre-A financing in 2020 and continues to advance as an innovation-driven leader in rapid detection technology.
Co-Founders
Lei Zhang(Sales VP)
Graduated from Soochow University, he has more than ten years of working experience in the medical industry and focuses on promoting the practice and development of technology in hospitals. He has successively served as domestic sales manager and director in companies such as Sweden Contec, Roche Diagnostics, and general manager of Shanghai Jiuxiang Medical Company.
David Chen(Research & Development VP)
He holds a master's degree in biology from Soochow University and has nearly 20 years of experience in R&D, production, strategy, and other operations and management in biotechnology service and product R&D enterprises. He has successively served as vice president of operation and development and senior manager of the production department in two listed international biotechnology companies.
Harriet Huang(Operations VP)
She holds a master's degree in biology from Soochow University and has more than ten years of experience in R&D, registration, production, quality, and marketing operations and management in in vitro diagnostic reagent enterprises. She has experience in the full life cycle management of products and product access in multiple countries.
Jun Li (Scientific Advisor)
He is a Ph.D. in biochemistry from the University of Utah in the United States, an internationally renowned expert in biopharmaceutical R&D, a "Double Creation" talent in Jiangsu Province, and a Gusu talent in Suzhou. He is the general manager of a domestic biomedical company and has more than 20 years of experience in bioengineering and drug R&D. He once served as a senior researcher and project leader in the Novartis Institutes for BioMedical Research in the United States.